Patent Claims Allowed Covering Samaritan’s Alzheimer’s Memory Recovery Drug In Australia
May 15th 2008Drug InformationAlzheimer's / Dementia News XML/RSS Feed
Samaritan Pharmaceuticals (OTCBB:SPHC), a biopharmaceutical company committed to commercializing new innovative therapeutic drugs, has received notification that the claims in the patent application for “Neuroprotective Spirostenol Pharmaceutical Compositions” covering Caprospinol (SP-233) have been allowed by the Australian Patent Office. The hallmark of Alzheimer’s disease is plaque formation in areas of the brain that control memory and thinking skills.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
